Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.
Scope of the Report:
The global average price of narcolepsy drug is in the decreasing trend, from 43.3 K USD/Kg in 2012 to 35.7 K USD/Kg in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of narcolepsy drug includes antioxidants type, stimulants type and other types, and the proportion of antioxidants type in 2016 is about 78% in the world.
Narcolepsy drug is widely used for daytime extreme sleepiness, cataplexia and other field. The most proportion of narcolepsy drug is used for cataplexia, and the consumption proportion in 2016 is about 57%.
The worldwide market for Narcolepsy Drug is expected to grow at a CAGR of roughly 10.4% over the next five years, will reach 3310 million US$ in 2024, from 1830 million US$ in 2019, according to a new WMR study.
This report focuses on the Narcolepsy Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
Daytime Extreme Sleepiness
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Narcolepsy Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Narcolepsy Drug, with price, sales, revenue and global market share of Narcolepsy Drug in 2017 and 2018.
Chapter 3, the Narcolepsy Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Narcolepsy Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Narcolepsy Drug market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Narcolepsy Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.